CELLINK is setting up a new lab that will enable the company to develop better kidney, heart, liver and lung tissue models for use in pharmaceutical development. Located in the BioVentureHub, at the heart of AstraZeneca's R&D Gothenburg site, the new lab will be staffed by a team of four scientists and researchers. They will focus on developing opportunities for customers and partners to bioprint using any type of cells relevant to the targeted applications.